Leena Gandhi MD

Associate Professor, Dana-Farber Cancer Institute, Harvard Medical School

450 Brookline AveBoston, MA 02215
Phone+1 617-632-6049
Fax+1 617-632-2630

Dr. Gandhi is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gandhi's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2008
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2002 - 2004
New York University School of MedicineClass of 2002

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2005 - 2027
NY State Medical License 2016 - 2023
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2010 Jul 28
COMPLETED
PHASE2
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
COMPLETED
PHASE2
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE1

Publications & Presentations

PubMed

1 citations
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières
Clinical Lung Cancer. 2026-03-01
1 citations
Mapping MAGE-A4 expression in solid cancers for targeted therapies.
Christin Habigt, Sylvie Rottey, Iben Spanggaard, Juanita S Lopez, Elena Garralda
Frontiers in Oncology. 2025-01-01
7 citations
Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study.
Kenneth L Kehl, Tali Mazor, Pavel Trukhanov, James Lindsay, Matthew R Galvin
JCO Precision Oncology. 2024-03-01

Lectures

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

NexImmune Announces Appointment of Dr. Leena Gandhi to Its Board of DirectorsMay 10th, 2022
Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to Its Board of DirectorsFebruary 28th, 2022
Lung Cancer Awareness Month: 2021 Immunotherapy Research UpdatesNovember 1st, 2021